DermaShield® provides a massive reduction of potential skin reactions and allergies. It minimises the risks of:

• Type IV allergies, because it is free of accelerators

• Type I allergies, because it is free of natural rubber latex

Its poly-chloroprene composition offers a high level of resistance to ethanol and isopropanol. It is an ideal choice for handling cytostatics (see brochure: ACPP: Ansell Cytostatic Permeation Program). Quality control is assured by AQL inspection methods: 0.65 for pinholes (water leak test) before packing. Moreover, in rigorous Personal Protective Equipment (PPE) testing, the DermaShield® is certified to EN 420 and EN 374.

Thanks to its unique formulation of poly-chloroprenes, DermaShield® offers comfort comparable to natural rubber latex with excellent flexibility and elongation. Wearers enjoy greater dexterity and a natural fit that matches their hands. The glove’s synthetic polyurethane inner coating makes donning easy. Its special external surface treatment, as well as constant grip value monitoring online and during post-processing, ensure consistent and adept handling of products. Moreover, the long cuff gives extra wrist and forearm protection.

According to the World Health Organisation, between now and 2020 the cancer rate will rise by 50% to about 15 million new cases a year worldwide. This sharp increase will mainly be due to ageing populations, current smoking habits and growing numbers of people with unhealthy lifestyles. One of the most frequently used treatments for cancer is chemotherapy. Unfortunately it is well known that cytostatic agents are potentially hazardous for the manipulator (pharmacist assistant, nurse and surgeon, etc.). Cytostatics are recognised to be mutagenic, carcinogenic and teratogenic. Other potential effects include decreased fertility, foetal malformation, abortion, extra-uterine pregnancy and high toxicity for certain organs.

To help address the risks of cytostatics to healthcare workers, Ansell has established the Ansell Cytostatic Permeation Program*.

• To contribute to better protection for healthcare personnel handling cytostatics

• To present results corresponding to real-life condition

For more information on the ACPP visit Ansellcares